Credit Suisse’s PhenomeX Inc. Common Stock CELL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-2
Closed -$5 3866
2022
Q4
$5 Sell
2
-316
-99% -$833 ﹤0.01% 3833
2022
Q3
$1K Buy
318
+265
+500% +$1.13K ﹤0.01% 3982
2022
Q2
$0 Buy
+53
New +$278 ﹤0.01% 4490
2021
Q3
Sell
-12,265
Closed -$550K 4604
2021
Q2
$550K Buy
+12,265
New +$569K ﹤0.01% 3786

Other funds holding CELL

Credit Suisse's CELL Position: Q1 2023 in Review

Credit Suisse sold out of PhenomeX Inc. Common Stock (CELL) in Q1 2023, closing a stake of 2 shares — an estimated $5 sold.

Credit Suisse first reported a position in CELL in Q2 2021 and held it in 4 quarters. The position peaked at $550K in Q2 2021. 102 funds tracked by Wall St. Rank hold CELL as of Q1 2023.

  • Credit Suisse reported no remaining PhenomeX Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 2 PhenomeX Inc. Common Stock shares in Q1 2023, an estimated $5.
  • Credit Suisse first reported a position in PhenomeX Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Credit Suisse's PhenomeX Inc. Common Stock position peaked at $550K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.